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Abstract
Background—Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) 
dimethylarginine are established predictors of total and cardiovascular mortality. However, the 
predictive capacity of ADMA and SDMA for hospital and 3-months mortality of patients with 
acute heart failure (AHF) is unknown.
Methods & results—Out of 152 included AHF patients, 79 (52%) were female, and the mean 
patient age was 75.2 ± 10.3 years. Hospital and three-month mortality rates were 14.5% and 
27.4%, respectively. Serum ADMA and SDMA levels at admission, determined by reversed phase 
high performance liquid chromatography, were higher in patients having at least one of the three 
signs implying venous volume overload (enlarged liver, ascites, peripheral edema), a consequence 
of right-sided heart failure, compared to patients without those signs. Univariable logistic 
regression analyses revealed a significant positive association of ADMA and SDMA 
concentrations with hospital mortality [odds ratio (OR) and 95% confidence interval (CI) per 
standard deviation (SD) increase: 2.22 (1.37–3.79), p = 0.002, and 2.04 (1.34–3.18), p = 0.001, 
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respectively], and 3-months mortality [2.06 (1.36–3.26), p = 0.001, and 2.52 (1.67–4.04), p < 
0.001, respectively]. These associations remained significant after adjusting for age, sex, mean 
arterial pressure, low-density lipoprotein cholesterol, glomerular filtration rate, and N-terminal 
pro-brain natriuretic peptide.
Conclusions—We conclude that ADMA and SDMA concentrations are associated with hospital 
and 3-month mortality and are increased by venous volume overload in AHF patients.
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1 Introduction
Despite achievements in prevention, diagnosis and treatment, heart failure (HF) is still a 
frequent cause of death and disability worldwide [1]. HF is defined by the European Society 
of Cardiology (ESC) as an abnormality of cardiac structure and function, resulting in failure 
of the heart to deliver oxygen at a rate commensurate with the requirements of the 
metabolizing tissues [2,3]. Acute heart failure (AHF) denotes the rapid onset of, or changes 
in, symptoms and signs of HF [3]. Accurate prognostic biomarkers are crucial for risk 
assessment, timely and appropriate therapeutic interventions and the overall management of 
AHF.
Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are 
products of intracellular proteolysis of proteins containing methylated arginines [4]. Serum 
concentrations of ADMA and SDMA are determined by the rate of their release from the 
cells, tissue degradation and the rate of renal elimination [4]. Both ADMA and SDMA exert 
a negative effect on vascular nitric oxide (NO) bioavailability [5], implicating their role in 
the cardiovascular pathophysiology related to endothelial dysfunction [6,7]. In line with this, 
both ADMA and SDMA have been found to independently predict total and cardiovascular 
mortality [8–10]. In addition, it has been shown that ADMA levels are predictive for disease 
progression and adverse long-term outcomes in chronic systolic HF patients [11].
2 Theory
Since it is known that ADMA and SDMA are associated with the cardiovascular 
pathophysiology as well as mortality, but the association with AHF mortality has not yet 
been studied, the aim of the present study was therefore to examine the predictive capacity 
of ADMA and SDMA for hospital and 3-months mortality in AHF patients.
3 Methods
3.1 Study design and patients
We previously reported on study design, inclusion and exclusion criteria as well as patient 
characteristics for our AHF cohort [12,13]. Written informed consent was obtained from 
each patient and the study was conducted in adherence to the ethical guidelines of the 
Declaration of Helsinki [14], as reflected in a priori approval by the Ethics Committees of 
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the University Hospital Centre Sisters of Charity, Zagreb, Croatia and the Medical 
University of Graz, Austria. All patients were treated according to the ESC Guidelines for 
AHF [3,15].
3.2 Laboratory procedures
The collection of blood samples, standard laboratory methods, and the determination of the 
N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) concentration were described in our 
previous reports on our AHF cohort [13,16]. ADMA and SDMA levels were determined 
according to our previous work [8,9]. The concentration of fibrinogen was determined with a 
blood coagulometer (BCS XP, Siemens, Germany). The levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) were determined with Architect c8000, Abbott 
2013 (Chicago, IL, USA).
3.3 Statistical analyses
Categorical data are shown as absolute and relative frequencies, whereas continuous data are 
summarized as median and range (minimum to maximum) due to the skewed distribution of 
many of the laboratory parameters. Patients with and without signs of venous volume 
overload were compared by the Mann-Whitney U test and Fisher's exact test. Correlations 
between ADMA, SDMA and various laboratory and clinical parameters were determined by 
the Spearman correlation coefficient. Univariable and multivariable logistic regression 
analyses were used to examine the impact of ADMA and SDMA levels on hospital and 3-
month mortality. In the multivariable analyses, we adjusted for age, sex, NT-proBNP, GFR, 
mean arterial pressure (MAP) as well as low-density lipoprotein (LDL) cholesterol and 
checked the variance inflation factor to prevent multi-collinearity among the covariates. 
Results are presented as odds ratio (OR) and the respective 95% confidence interval (CI) per 
standard deviation (SD) increase. Presentation on the SD scale is warranted because ADMA 
and SDMA values were normally distributed. R version 3.4.2 was used for all statistical 
analyses.
4 Results
4.1 Patients' clinical characteristics and laboratory parameters
The patients' baseline characteristics have been described elsewhere [12]. Out of 152 
included patients, 79 (52%) were female and the mean (SD) age was 75.2 ± 10.3 years. 
According to the New York Heart Association Functional Classification (NYHA), 11 (7.2%) 
patients belonged to class 2, 83 (54.6%) to class 3, and 58 (38.2%) to class 4. Frequent 
comorbidities were hypertension (89.5%), type 2 diabetes mellitus (51.7%), hyperlipidemia/
hypertriglyceridemia (39.5%), and hypercholesterolemia (38.8%). Regarding previous 
medication 41 (27%) of patients were treated with statins, 67 (45%) with β-blockers, 86 
(57%) with angiotensin-converting enzyme inhibitors (ACEI), and 25 (16.6%) with 
amlodipine. Worsening of chronic HF occurred in 105 (69.1%) patients and 61 (42.4%) had 
a preserved ejection fraction. Regarding signs at admission reflecting venous volume 
overload as a consequence of right-sided HF, 53 (34.9%) patients had an enlarged liver, 21 
(13.8%) had ascites, and 105 (69.1%) had a peripheral edema (with possible overlaps); 110 
(72.4%) patients had at least one of the signs and 11 (7.2%) had all three. Median (range) 
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length of hospitalization was 9 (0.0–85.0) days. Twenty-two (14.5%) patients died in the 
hospital; the number increased to 40 (27.4%) three months after admission. Median and 
range for ADMA and SDMA levels were 0.8 (0.5–1.4) μmol/L and 1.4 (0.5–4.3), 
respectively; fibrinogen concentration was 3.6 (1.1–12.1) g/L and the levels of ALT and 
AST were 23.0 (6.0–623.0) U/L and 27.0 (10.0–666.0), respectively. Other laboratory 
parameters have been reported previously [16].
4.2 Impact of venous volume overload on serum levels of laboratory parameters and 
MAP
To examine whether venous volume overload, a consequence of right-sided HF, affects 
serum levels of ADMA, SDMA, various laboratory parameters, and MAP, we compared 
their levels in patients with at least one of the three signs implying venous volume overload 
(enlarged liver, ascites or peripheral edema) to those without. As shown in Table 1, the 
concentrations of ADMA, SDMA, and CRP were significantly higher in patients with signs 
whereas the concentrations of total serum proteins, fibrinogen, total cholesterol, LDL 
cholesterol, HDL-cholesterol, triglycerides, and MAP were significantly decreased. The 
kidney function markers, GFR, urea, and creatinine as well as serum albumin, a marker for 
the biosynthetic capacity of the liver, and NT-proBNP, a marker for HF severity, as well as 
ALT and AST were similar in patients with and without signs.
4.3 Correlation of ADMA and SDMA concentrations with laboratory and clinical 
parameters
As shown in Table 2 the concentrations of ADMA and SDMA were positively correlated 
with patients' age and negatively with MAP, GFR and fibrinogen. SDMA, (but not ADMA), 
was further positively correlated with urea, creatinine and NT-proBNP and negatively with 
the serum protein concentration, as well as the total and HDL cholesterol serum levels. No 
significant correlation with either ADMA or SDMA was observed for body mass index 
(BMI), interleukin-6 (IL-6), C-reactive protein (CRP), AST, ALT, serum albumin, LDL 
cholesterol, triglycerides, left ventricular ejection fraction (LVEF), and length of 
hospitalization. Finally, ADMA and SDMA levels were positively correlated with each other 
(r = 0.47, p < 0.001).
4.4 Logistic regression analyses
The association of ADMA and SDMA with hospital and 3-month mortality in AHF patients 
was examined by logistic regression analyses (Table 3). The univariable analyses showed a 
significant positive association of both ADMA and SDMA levels with hospital and 3-month 
mortality. Importantly, these associations remained significant even after adjusting for age, 
sex, NT-proBNP, GFR, MAP and LDL cholesterol, the clinical and laboratory parameters 
that are known to be associated with mortality in HF patients.
5 Discussion
It is well established that accurate prognostic biomarkers are crucial for risk assessment, 
efficient therapeutic intervention, and overall management of HF. Previous studies 
highlighted both ADMA and SDMA as independent risk markers for total and 
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cardiovascular mortality and cardiovascular disease [8,10]. However, no study to date has 
examined the association of ADMA and SDMA with mortality in AHF patients.
The present study shows, for the first time, that high serum levels of ADMA or SDMA are 
independently associated with both hospital and 3-months mortality in AHF patients.
Furthermore, we show that ADMA and SDMA levels are increased in patients with signs 
implying venous volume overload (enlarged liver, peripheral edema, ascites), a consequence 
of right-sided HF. Given that different pathophysiological states and medication affect 
ADMA and SDMA serum levels, the baseline serum levels of these metabolites in our AHF 
patients reflect not only the impact of the AHF pathophysiology, but also, at least in part, the 
impact of the associated comorbidities and medication [5]. In the present study, 
comorbidities and prior medication were neither associated with mortality nor did they affect 
the association of ADMA and SDMA with mortality (Supplementary Tables 1–3).
The crucial role of endothelium-derived NO in the maintenance of a normal cardiac function 
and the inhibition of adverse ventricular remodeling is well established [17,18]. In line with 
this, it has been shown that administration of NO improves the left ventricle diastolic 
function in HF patients [19] and that chronic inhibition of the endogenous NO production is 
associated with severe myocardial fibrosis in animal models [20]. Accordingly, the well-
documented diminishing effect of ADMA and SDMA on the vascular NO bioavailability, 
due to inhibition of the endothelial nitric oxide synthase (eNOS) activity by ADMA and the 
interference of SDMA with the utilization of the eNOS substrate L-arginine [4,5], may well 
explain the link between ADMA, SDMA and AHF mortality. Additionally, considering that 
HDL function, including the activation of the eNOS/NO pathway [21], is attenuated by 
methylated arginine species [22], it is conceivable that ADMA and SDMA exert deleterious 
effects through HDL dysfunction. Moreover, increased ADMA and SDMA levels in AHF 
patients with signs implying venous volume overload, a condition associated with venous 
congestion as well as hemodynamic and metabolic perturbations [23], suggest an association 
of ADMA and SDMA with a more severe stage of AHF. This additionally supports the 
association of ADMA and SDMA with mortality. Indeed, an increase (albeit not statistically 
significant) in hospital (16.4% vs. 9.5%, p = 0.439) and 3-month mortality (31.7% vs. 
16.7%, p = 0.069) was observed in patients with at least one sign, compared to patients 
without.
In line with previous studies, we observed a strong association of SDMA and a less 
profound association of ADMA with parameters indicating renal function [24]. In contrast to 
the reported association of venous volume overload with impaired renal function [25], we 
did not observe that the markers of kidney function (including GFR, urea and creatinine), 
were altered by venous volume overload (Table 1). This indicates that venous volume 
overload defined by the presence of enlarged liver, ascites or peripheral edema, was not 
accompanied by renal congestion or that the degree of renal congestion was insufficient to 
affect renal function.
The negative association of SDMA, but not of ADMA, with serum proteins, as well as total 
and HDL-cholesterol might be a consequence of a positive association of SDMA with the 
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severity of HF, which is known to be positively associated with metabolic impairment and a 
catabolic dominance [23]. Indeed, SDMA, (but not ADMA) levels, were strongly positively 
correlated with NT-proBNP, an established marker for the severity of HF (Table 2).
It is conceivable that intestinal congestion, and thereby accompanied intestinal edema, as 
well as an impaired nutrient absorption, together with a diminished biosynthetic activity of 
the congested liver, underlie the decreased circulating proteins and lipids in our patients with 
venous volume overload. This would be in line with a previous study suggesting that hepatic 
congestion, a consequence of right-sided HF, rather than hypo-perfusion, causes liver 
dysfunction [26].
Since in the present study ALT and AST levels were similar in patients with and without 
signs, it seems that venous volume overload was not associated with any hepatocyte damage, 
but rather with an impaired hepatic biosynthetic activity.
Interestingly, in contrast to decreased levels of total serum proteins and fibrinogen, the levels 
of albumin, a marker for nutritional status and the biosynthetic capacity of the liver, were not 
altered in patients with signs (Table 1). Unaltered albumin levels probably reflect the 
contribution of certain compensating mechanisms, namely the net transfer of extravascular 
albumin into the intravascular pool, and the decreased albumin catabolic rate, which are both 
operative for albumin [27,28], but not fibrinogen [29], when biosynthetic capacity of the 
liver is diminished.
Quite opposite to what was found for serum proteins and lipids, the levels of ADMA and 
SDMA were increased in patients with at least one sign implying volume overload. Several 
potential mechanisms may explain this observation: First, increased ADMA and SDMA 
levels have previously been observed in various pathophysiological conditions associated 
with increased protein-turnover [30,31]. An increased rate of protein-turnover, likely caused 
by limited delivery of nutrients due to intestinal edema and impaired intestinal absorption, 
may in turn explain increased ADMA and SDMA levels in AHF patients with signs. Second, 
it might be that tissue congestion augments the methylation rate of arginine residues in 
cellular proteins, or the release of ADMA and SDMA into the circulation. Importantly, 
increased gene and protein expression of the ADMA-degrading enzyme, 
dimethylaminohydrolases-1, was observed in end-stage failing human hearts upon 
ventricular unloading following the support with a left ventricular assist device [32]. This 
finding strongly supports the notion that the decreased expression and activities of ADMA- 
and SDMA-degrading enzymes in the congested tissue might be responsible for increased 
ADMA and SDMA serum levels when there is a venous volume overload, as observed in 
our patients with signs. Accordingly, it is likely that the alleviation of congestion by 
diuretics decreased ADMA and SDMA levels in our AHF patients upon hospitalization. 
Furthermore, other pharmacological interventions, such as angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, or some statins, are capable of decreasing ADMA 
levels [5] and were used for treatment of our AHF patients. Therefore, it is conceivable that 
either one or a combination of these pharmacological approaches might have affected 
ADMA and SDMA levels and consequently the effect thereof on mortality. However, 
medication on the first and second day of hospitalization was neither associated with 
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mortality nor did it affect the association of ADMA and SDMA with mortality 
(Supplementary Tables 4–7).
We found that ADMA and SDMA were not significantly correlated with IL-6 or CRP serum 
levels, but were negatively correlated with fibrinogen (Table 2), an acute phase protein that 
was itself positively correlated with CRP (r = 0.33, p < 0.001) and IL-6 (r = 0.22, p = 0.007). 
This suggests that in our AHF patients both ADMA and SDMA levels were not affected by 
the patients' inflammatory status. Accordingly, the negative correlations of both ADMA and 
SDMA with fibrinogen conceivably reflect that they are regulated into opposite directions by 
venous volume overload, a state that was accompanied by increased CRP levels in the 
present study (Table 1).
5.1 Study limitations
There are several limitations to our present study: The design does not allow us to draw 
conclusions about cause and effect for the pathophysiological processes involved in the 
regulation of ADMA and SDMA serum levels. Furthermore, we cannot provide a 
mechanistic explanation on how ADMA and SDMA affect mortality. In addition, by 
defining venous volume overload solely as the presence of signs implying volume overload, 
we were unable to test the impact of the extent of volume overload, as would have been 
possible with data on the right ventricle end diastolic diameter or the diameter of the right 
atrium. Finally, the moderate number of participants (n = 152) in this monocentric study 
influences the statistical power of our analyses. Therefore, further large studies are needed to 
confirm our results.
6 Conclusions
Based on our results, we conclude that serum concentrations of both ADMA and SDMA are 
associated with hospital and 3-month mortality and are increased by venous volume 
overload in AHF patients.
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HF heart failure
AHF acute heart failure
ADMA asymmetric dimethylarginine
SDMA symmetric dimethylarginine
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NO nitric oxide
NT-proBNP N-terminal pro-brain natriuretic peptide
GFR glomerular filtration rate
MAP mean arterial pressure
LDL low-density lipoprotein
HDL high-density lipoprotein
NYHA New York Heart Association Functional Classification
CRP C-reactive protein
(IL-6) interleukin-6
BMI body mass index
ALT alanine aminotransferase
AST aspartate aminotransferase
CI confidence interval
ESC European Society of Cardiology
eNOS endothelial nitric oxide synthase
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Table 1
Laboratory parameters and MAP in patients with or without sign(s) implying volume 
overload.
No sign
(N = 42)
Sign(s)
(N = 110)
p-Value
ADMA (μmol/L) 0.7 (0.5–1.2) 0.9 (0.5–1.4) 0.001
SDMA (μmol/L) 1.1 (0.5–2.6) 1.5 (0.5–4.3) 0.002
GFR (ml/min/1.73 m2) 50.6 (19.6–105.7) 51.0 (15.0–104.8) 0.517
Urea (mmol/L) 8.0 (3.0–64.0) 8.0 (3.0–41.0) 0.063
Creatinine (μmol/L) 48.0 (18.6–138.0) 47.0 (6.0–151.0) 0.534
NT-proBNP (ng/mL) 8.3 (0.7–70.0) 9.6 (0.2–70.0) 0.214
ALT (U/L) 23.0 (7.0–145.0) 23.0 (6.0–623.0) 0.610
AST (U/L) 24.0 (14.0–369.0) 28.0 (10.0–666.0) 0.843
IL-6 (pg/mL) 19.2 (0.4–300.0) 21.4 (1.2–300.0) 0.968
CRP (μg/mL) 4.5 (0.2–71.6) 11.5 (0.5–247.4) 0.004
Protein (g/L) 71.5 (36.0–87.0) 66.0 (31.0–86.0) <0.001
Fibrinogen (g/L) 3.8 (2.4–12.1) 3.5 (1.1–9.4) 0.003
Albumin (g/L) 39.5 (24.0–72.0) 40.0 (21.0–62.0) 0.580
Total cholesterol (mmol/L) 4.5 (2.5–9.1) 3.8 (1.7–8.5) 0.001
LDL-cholesterol (mmol/L) 2.7 (1.3–6.3) 2.2 (0.8–6.1) 0.004
HDL-cholesterol (mmol/L) 1.1 (0.4–2.3) 0.9 (0.3–3.6) 0.027
Triglycerides (mmol/L) 1.2 (0.6–4.3) 1.0 (0.5–3.2) 0.002
MAP (mm Hg) 109.2 (65.0–158.3) 100.0 (53.3–160.0) 0.034
Data are presented as median and range (minimum to maximum). Differences between patients without any sign and those with at least one of the 
three signs implying venous volume overload (enlarged liver, peripheral edema, ascites) were tested with the Mann-Whitney U test; significant 
differences are depicted in bold.
ADMA, asymmetric dimethylarginine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive 
protein; GFR, glomerular filtration rate; IL-6, interleukin-6; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MAP, mean arterial 
pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; SDMA, symmetric dimethylarginine.
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Table 2
Correlation analyses of ADMA and SDMA concentrations with clinical and laboratory 
parameters.
ADMA (μmol/L) SDMA (μmol/L)
r p-Value N r p-Value N
Age (years) 0.28 0.001 131 0.26 0.002 137
BMI (kg/m2) −0.10 0.250 131 −0.17 0.054 137
GFR (ml/min/1.73 m2) −0.20 0.021 130 −0.66 <0.001 136
Urea (mmol/L) 0.13 0.137 130 0.51 <0.001 136
Creatinine (mol/L) 0.07 0.397 130 0.56 <0.001 136
NT-proBNP (pg/mL) 0.15 0.094 126 0.50 <0.001 131
AST (U/L) −0.07 0.426 128 0.08 0.370 134
ALT (U/L) −0.15 0.096 127 −0.06 0.504 133
IL-6 (pg/mL) −0.01 0.876 131 0.17 0.053 137
CRP (μg/mL) 0.02 0.785 129 0.14 0.094 135
Protein (g/L) −0.11 0.227 129 −0.24 0.006 134
Fibrinogen (g/L) −0.25 0.005 126 −0.24 0.006 132
Albumin (g/L) −0.08 0.357 128 −0.13 0.121 134
Total cholesterol (mmol/L) −0.14 0.113 131 −0.25 0.003 137
LDL-cholesterol (mmol/L) −0.08 0.373 131 −0.16 0.068 137
HDL-cholesterol (mmol/L) −0.17 0.060 131 −0.22 0.009 137
Triglycerides (mmol/L) 0.01 0.919 131 −0.06 0.506 137
MAP (mm Hg) −0.21 0.016 131 −0.33 <0.001 137
LVEF (%) 0.05 0.549 122 −0.17 0.052 127
Length of hospitalization (days) −0.02 0.785 129 0.15 0.081 135
Data are presented as Spearman correlation coefficient r, p-value, and number of available samples; significant correlations are depicted in bold.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GFR, glomerular filtration rate; 
HDL, high-density lipoprotein; IL-6, interleukin 6; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro brain natriuretic peptide; SDMA, 
symmetric dimethylarginine.
Int J Cardiol. Author manuscript; available in PMC 2019 June 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Potočnjak et al. Page 13
Table 3
Univariable and multivariable logistic regression analyses of hospital and 3-month 
mortality for ADMA and SDMA.
Unadjusted Adjusteda
OR (95% CI) p-Value Events/N OR (95% CI) p-Value Events/N
Hospital mortality
ADMA (μmol/L) 2.22 (1.37–3.79) 0.002 20/131 2.15 (1.17–4.29) 0.019 19/125
SDMA (μmol/L) 2.04 (1.34–3.18) 0.001 21/137 1.83 (1.01–3.39) 0.045 20/130
3-month mortality
ADMA (μmol/L) 2.06 (1.36–3.26) 0.001 34/126 2.28 (1.38–3.98) 0.002 32/120
SDMA (μmol/L) 2.52 (1.67–4.04) <0.001 37/132 1.88 (1.14–3.28) 0.017 35/125
OR and CI are presented on the SD scale (increase per 1 SD); SDs for ADMA and SDMA are 0.17 and 0.81 μmol/L, respectively.
a
The model was adjusted for age, sex, NT-proBNP, GFR, MAP and LDL-cholesterol. ADMA, asymmetric dimethylarginine; CI, confidence 
interval; GFR, glomerular filtration rate; LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal brain natriuretic 
peptide; OR, odds ratio; SD, standard deviation; SDMA, symmetric dimethylarginine.
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